Eris Lifesciences Limited IPO Message Board (Page 27)

@Septa Sir,
Dear Sir,
I hope that you have gone through the RHPs of Eris Lifesciences and Tejas.
I would like to know your detailed analysis and final opinion on these two IPOs please, Sir at the earliest.
Thanks.

Company''s bottom-line grew at a pace of 42% in last three year. If this trend continue for next year. Current year EPS is Rs 17.61, next year it will Rs 25. Pharma ind. PE is around 30, then this stock may list at around Rs.750,as market always discount forward EPS.

Eris LifeSciences IPO
GMP 40 Seller


* Mumbai Broker

Subscribe this IPO

Avoid..
Very high valuation...

Which is fair velue from this stock Eris ?

400

Eris LifeSciences IPO
GMP 82 – 84

Eris life
PREMIUM: 85-87

Can anyone suggest me a broker who opens minor demat and trading account. Any online broker or local broker based in gurgaon will do .

cheap & best:- ZERODHA

EDELWEISS WILL OPEN THE MINOR A/C IF U HAVE MINOR PANCARD.

avoid

91/92 premium

NAV as on March 31, 2017 was Rs.39.85 (Page #85 of RHP)
Eris 603+140 gmp=743
Book value=39.85
Price to book value=18.64

Peer Group (Page #86 of RHP):
GlaxoSmithKline Pharm pb=10.19 pe =62
Abbott India pb=6.49 pe=32.49
Sanofi India pb=5.37 pe=33.74
Pfizer pb=3.13 pe=22.79

603+147gmp=750 PE=43
TOO HIGH

I think this ipo is an avoid on the above valuations. Any views from experts and regulars on the board?

Dear Senior''s l have 400 shares of idfc bank @75 since last one year and there is no movement .can any body help shall I hold or sell.
I can keep for next 5 years

ERIS LIFE SCIENCES
PREMIUM : 111 SELLER ONLY
KOSTAK : 300-350

Kostak nill

May list around 40+ Premium

Friends suggest me apply or avoid this ipo allotment chance in Eris and Tejas is very hard

Tcs next bonus kB announce krega 2009 ke bad abhi nhi kiya hi

Given face value is Re.1/- And
Issue price Rs.600/- presuming
Then,
If we treat FV Rs.10/- then issue Price comes to Rs.6000/- a share.
I think this will be All time high historical​ premium to be charged by an Indian co. Eris.
Expert''s comments pl.

TCS

Pl. go through the following:


Here''s how TCS has fared from the day of its listing in 2004:

1) TCS came out with its IPO in the month of July, 2004; the price band was Rs. 775-Rs. 900. The issue price of TCS shares was fixed at Rs. 850.

2) TCS shares got listed on August 25, 2004 at a premium of 26.6 per cent at Rs. 1,076.

3) From August 25, 2004 till now, TCS has issued bonus shares twice in the ratio of 1:1 (one bonus share for every share held). The bonus shares were issued first on July 28, 2006 and later on June 16, 2009. So, an investor who bought just one share in TCS'' IPO, by investing Rs. 850, would have 4 shares of TCS by now.

4) The value of Rs. 850 invested in TCS in August 2004 would have gone up to Rs. 9,904.8 (stock price of Rs. 2,476.20 x 4 bonus shares) based on Friday''s closing price. This turns out to be a return of 1065 per cent over the last ten years or a CAGR of 27.8 per cent. This return is over and above the dividends paid by the company.

5) An investment of Rs. 850 in TCS IPO in 2004, would have earned a total dividend income of Rs. 733.5 by now.

*Eris Lifesciences Limited IPO update*

Opens On: 16-June-2017

Closes On: 20-June-2017

*Price Band: Rs. 600 to Rs. 603*

*Bid Lot: 24 Shares* & in multiple thereafter

*Face Value: Rs. 1/- per share*

Issue size: *Rs. 1732.50 Crs at lower band & Rs. 1741.16 Crs at upper band*

Employees Reservation: Rs. 9 Crs at lower band & Rs. 9.05 crs at upper band

Net Issue Size: *Rs. 1723.50 crs at lower band & Rs. 1732.12 crs at upper band*

Allocation:

*QIB : 75% of Net Issue* ( Rs. 1292.63 crs at lower band & *Rs. 1299.09 crs at upper band*)

*HNI: 15% of Net Issue* ( Rs. 258.53 crs at lower band & *Rs. 259.82 crs at upper band*)

*Retail: 10% of Net Issue* ( Rs. 172.35 crs at lower band & *Rs. 173.21 crs at upper band*)

Page 57 RHP
The following table summarizes details of the Offer:
Offer* Up to 28,875,000 Equity Shares aggregating up to Rs [●]
million
Of which
Employee Reservation Portion# 150,000 Equity Shares
Accordingly,
The Net Offer Up to 28,725,000 Equity Shares
Of which
QIB Category ## At least 21,543,750 Equity Shares
Of which:
Anchor Investor Portion 12,926,250 Equity Shares
Balance available for allocation to QIBs other than
Anchor Investors (assuming Anchor Investor Portion
is fully subscribed)
8,617,500 Equity Shares
Of which:
- Available for allocation to Mutual Funds only 430,875 Equity Shares
- Balance for all QIBs including Mutual Funds 8,186,625 Equity Shares
Non-Institutional Category Not more than 4,308,750 Equity Shares
Retail Category Not more than 2,872,500 Equity Shares
Equity Shares outstanding prior to and after the Offer 137,500,000 Equity Shares

CS Aman Jain Sir,
Thanks so much for explaining regarding the retail reservation​ quota rules in an IPO. That means this co does not meet all the listing criteria as per SEBI rules. Thanks once again.

AS MANY EXPERTS HAVE POSTED BEFORE THAT ANYTHING ABOVE 500 IS EXPENSIVE AND NOW PRICE IS FIXED AT 600 TO 603. SO SHOULD APPLY OR NOT. BECAUSE CANT TRUST GMP WE HAVE SEEN IN PREVIOUS IPOS.

As Eagleye nicely put " Suno sabki karo Mann ki"
@603
NP 240cr Mcap 8300 cr PE34
Sales 750 cr Mcap/Sales 11

@750
PE43
Mcap/sales 14

In 2010 piramal sold demestic formulation business which eris life does at 9 times Mcap to sales .....I don''t think I m smarter tjan legendary Mr Ajay Piramal who thought to exit at those valuation....if anything changed thereafter is that MKT has become lot more difficult now days in terms of competition n price regulations

IPO NOTE:

Eris LifeSciences IPO – Schedule – Page #290 of RHP

15th June – Anchor List
16h June – Offer Opens
20th June – Offer Closes
23st June – Finalisation of Basis of Allotment
27th June – Unblocking of ASBA
28th June – Credit to Demat Accounts
29th June – Listing on NSE & BSE


Eris LifeSciences IPO – Issue Information: (Final)

Issue Opens on: 16 June 2017
Issue Closes on: 20 June 2017
Issue Type: Book Built Issue IPO
Issue Size: 2,88,75,000 Equity Shares
Face Value: Re 1 per Equity Share
Issue Price: Rs.600 – Rs.603 per Equity Share (Tentative)
Market Lot: 24 Shares
Listing At: NSE, BSE

Equity Shares outstanding prior to the Issue = 13,75,00,000 Equity Shares
Offer for Sale of 2,88,75,000 Equity Shares @upper price band = Rs.1,741.16 Crores
Equity Shares outstanding after the Issue = 13,75,00,000 Equity Shares

Category-wise Break up:.
Anchor – 1,29,26,250 Shares = 779.45Crs
QIB – 86,17,500 Shares = 519.64Crs
NII – 43,08,750 Shares = 259.82Crs
RII – 28,72,500 Shares = 173.21Crs (Lot size: 24 = 119,688 Forms)
Empl – 1,50,000 Shares = 9.05Crs

Total Issue – 2,88,75,000 Equity Shares = 1741.16Crs.

Subscription required for 1X
RII = 119,688 Forms
NII = 259.82 Crs

Interest cost @6%p.a. for 7days = 69.386paise for 1X


Eris LifeSciences IPO – Financial Information (Basis of Valuation)

EPS for FY14-15 >>> Rs.6.49 (Page #84 of RHP)
EPS for FY15-16 >>> Rs.9.71 (Page #84 of RHP)
EPS for FY16-17 >>> Rs.17.61 (Page #84 of RHP)

RoNW for FY14-15 >>> 33.59% (Page #85 of RHP)
RoNW for FY15-16 >>> 44.64% (Page #85 of RHP)
RoNW for FY16-17 >>> 44.84% (Page #85 of RHP)

NAV as on March 31, 2017 was Rs.39.85 (Page #85 of RHP)

Peer Group (Page #86 of RHP):
GlaxoSmithKline Pharmaceuticals
Abbott India
Sanofi India
Pfizer




Eris LifeSciences IPO
Market Estimates of oversubscription:

Category-wise:

1X QIB(Net) = 519.64Crs – assuming applications of 10KCrs. = 20X oversubscription

1X NII = 259.82Crs – assuming applications of 45KCrs. = 175X oversubscription

1X RII = 119,688 Forms – assuming 10L forms. = 8.355X oversubscription (applic-wise)
i.e. average 2.87 shares per form


Eris LifeSciences IPO

GMP 143 – 145
Kostak 350 – 400

Price band fixed. 600-623.

This is not the best practices. Only 10% left for the retailers. I think, management & BRLM do not want to hand over their stack to retailers as retailer portion is always sold on listing day which increase the volatility.

I will prefer to sell my application in grey market. I am from Delhi. Anybody wishes to purchase 6 application, can leave message.